Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Durable Improvement Shown in FVC and Across Multiple Measures
April 30, 2023 14:10 ET
|
Pliant Therapeutics, Inc.
Bexotegrast was well tolerated up to 40 weeks of treatment with no drug-related serious adverse events Combination of bexotegrast with standard of care reduced FVC decline by 80% relative to standard...
Pliant Therapeutics to Participate in the 22nd Annual Needham Healthcare Conference
April 12, 2023 08:01 ET
|
Pliant Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., April 12, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel...
Pliant Therapeutics Announces Poster Presentations at the 2023 American Thoracic Society International Conference
March 27, 2023 08:01 ET
|
Pliant Therapeutics, Inc.
Posters include data across biomarker, translation and clinical studies supportingdevelopment of bexotegrast (PLN-74809), a dual-selective inhibitor of αvβ6/αvβ1 integrins, in IPF Two posters...
Pliant Therapeutics Announces Positive DSMB Safety Review and Initiation of Enrollment of Phase 2a Trial of Bexotegrast (PLN-74809) at 320 mg Dose in Primary Sclerosing Cholangitis
March 13, 2023 08:01 ET
|
Pliant Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., March 13, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2022 Financial Results
March 09, 2023 16:05 ET
|
Pliant Therapeutics, Inc.
- Positive data from bexotegrast INTEGRIS-IPF 320 mg dose group demonstrated a continued favorable safety profile and statistically significant increases in FVC - INTEGRIS-IPF 320 mg dose 24-week...
Pliant Therapeutics Announces Appointments of Darren Cline and Thomas McCourt to Board of Directors
March 08, 2023 16:01 ET
|
Pliant Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., March 08, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel...
Pliant Therapeutics to Participate in Upcoming Investor Events
March 01, 2023 08:01 ET
|
Pliant Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel...
Pliant Therapeutics to Participate in Upcoming Investor Events
February 07, 2023 08:01 ET
|
Pliant Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel...
Pliant Therapeutics Announces FDA Clearance of Investigational New Drug Application for PLN-101095, A Novel Integrin Inhibitor for the Treatment of Solid Tumors
February 02, 2023 08:02 ET
|
Pliant Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel...
Pliant Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
January 27, 2023 16:03 ET
|
Pliant Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 27, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel...